Juan Du

Dr. Juan Du

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ZGZhe Gao
Zhe Gao
JDJuan Du
Juan Du
This narrative review examines the therapeutic potential of Erastin and its derivatives for endometriosis (EMS) by integrating mechanistic, preclinical, and translational perspectives. We conducted a focused review of literature from PubMed and Web of Science Core Collection (WoSCC) through August 2025; following a systematic screening and de-duplication process, 91 studies were included for synthesis. The evidence indicates that within the iron-rich, ROS-prone microenvironment of EMS, Erastin inhibits the system Xc− transporter, depletes intracellular glutathione (GSH), and inactivates GPX4, thereby driving ferroptosis in ectopic endometrial stromal cells. This process engages a coordinated network of regulated cell death that extends beyond ferroptosis to include crosstalk with necroptosis and pyroptosis, while being critically modulated by ferritinophagy and the paradoxical role of defective mitophagy. Despite the development of next-generation analogs with improved pharmacological properties, clinical translation is constrained by a narrow therapeutic window due to on-target and off-target toxicities. To overcome these limitations, we propose that future strategies must prioritize lesion-focused drug delivery, such as nanocarriers and triggerable prodrugs, alongside biomarker-guided treatment regimens to decouple efficacy from systemic risk, paving a credible path for the clinical application of Erastin-class agents in EMS.

1 December 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
XHXiang Hu
Xiang Hu
MZMingya Zhu
Mingya Zhu
QZQin Zhou
Qin Zhou
ZLZimo Li
Zimo Li
LLLiping Luo
Liping Luo
JDJuan Du
Juan Du
Polycystic ovary syndrome (PCOS) is a prevalent and multifaceted endocrine disorder characterized by hyperandrogenism, ovarian dysfunction, and insulin resistance. This review aims to synthesize current evidence from both allopathic medicine and Traditional Chinese Medicine (TCM) to clarify the pathophysiological mechanisms of PCOS and evaluate the therapeutic potential of integrative management strategies. We first outline key epidemiological, genetic, and hormonal features that underpin PCOS, with particular emphasis on insulin resistance, chronic inflammation, and dysregulated gonadotropin secretion. We then summarize core TCM treatment principles and describe how herbal medicine, acupuncture, and combined therapies modulate endocrine pathways, improve metabolic homeostasis, and regulate immune-inflammatory responses. Clinical studies further suggest that TCM-based interventions may enhance ovulatory function, improve metabolic parameters, and alleviate hyperandrogenic symptoms, supporting their complementary role alongside allopathic treatments. Finally, current limitations-including variability in TCM pattern diagnosis, heterogeneity of herbal preparations, and methodological constraints in mechanistic research-are highlighted to guide future investigations. Overall, this review underscores the clinical relevance and potential value of integrative approaches that bridge traditional and modern medical frameworks in the comprehensive management of PCOS.

Verified
Journal Article
Open access
PDF file
JDJuan Du
Juan Du
ZLZili Lv
Zili Lv
XLXiaohong Luo
Xiaohong Luo
Studies have shown that the iron concentration in the peritoneal fluid of women is associated with the severity of endometriosis. Therefore, investigation of iron metabolism-related genes (IM-RGs) in endometriosis holds significant implications for both prevention and therapeutic strategies in affected patients. Differentially expressed IM-RGs (DEIM-RGs) were identified by intersecting IM-RGs with differentially expressed genes derived from GSE86534. Mendelian randomization analysis was employed to determine DEIM-RGs causally associated with endometriosis, with subsequent verification through sensitivity analyses and the Steiger test. Biomarkers associated with IM-RGs in endometriosis were validated using expression data from GSE86534 and GSE105764. Functional annotation, regulatory network construction, and immunological profiling were conducted for these biomarkers. Single-cell RNA sequencing (scRNA-seq) (GSE213216) was utilized to identify distinctively expressed cellular subsets between endometriosis and controls. Experimental validation of biomarker expression was performed via reverse transcription–quantitative polymerase chain reaction (RT-qPCR). BMP6 and SLC48A1, biomarkers indicative of cellular BMP response, were influenced by a medicus variant mutation that inactivated PINK1 in complex I, concurrently enriched by both biomarkers. The lncRNA NEAT1 regulated BMP6 through hsa-mir-22-3p and hsa-mir-124-3p, while SLC48A1 was modulated by hsa-mir-423-5p, hsa-mir-19a-3p, and hsa-mir-19b-3p. Immune profiling revealed a negative correlation between BMP6 and monocytes, whereas SLC48A1 displayed a positive correlation with activated natural killer cells. scRNA-seq analysis identified macrophages and stromal stem cells as pivotal cellular components in endometriosis, exhibiting altered self-communication networks. RT-qPCR confirmed elevated expression of BMP6 and SLC48A1 in endometriosis samples relative to controls. Both BMP6 and SLC48A1 were consistently overexpressed in endometriosis, reinforcing their potential as biomarkers. Moreover, macrophages and stromal stem cells were delineated as key contributors. These findings provide novel insights into therapeutic and preventive approaches for patients with endometriosis.

12 May 2025 in Taiwanese Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
ZGZhe Gao
Zhe Gao
JDJuan Du
Juan Du

14 July 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
WXWenyu Xu
Wenyu Xu
JDJuan Du
Juan Du
The survival of ectopic endometrial lesions in endometriosis critically depends on their ability to evade immune recognition and clearance by the host, a process known as immune evasion. Recent studies suggest that this process is not driven by a single factor but rather results from a multidimensional, interactive regulatory network involving immune dysregulation, epigenetic remodeling, and metabolic reprogramming. The pathophysiology of endometriosis is characterized by reduced cytotoxic activity and functional exhaustion of effector immune cells, along with excessive activation and expansion of immunosuppressive cells, affecting both innate and adaptive immunity. The overexpression of immune checkpoint molecules further impairs immunological clearance. DNA methylation, histone modifications, and non-coding RNAs contribute to immune cell tolerance by stabilizing repressive transcription programs and silencing pro-inflammatory genes. These epigenetic mechanisms maintain a sustained immunosuppressive state through direct regulation of immune-related genes and hormone-metabolizing enzymes. Additionally, the hypoxic environment of ectopic lesions stimulates glycolysis, leading to the accumulation of metabolites such as lactate. Beyond directly impairing immune cell function, these metabolites act as signaling molecules or cofactors for epigenetic enzymes, thereby influencing chromatin states and gene expression, thus mechanistically and functionally linking metabolism to epigenetics. This review aims to systematically unravel this multidimensional mechanism, elucidate its synergistic role in disease progression, and potentially pave the way for future combined therapeutic strategies targeting this complex pathway. Such approaches offer a novel and promising means to overcome immune evasion and clinical resistance in endometriosis.

1 September 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JDJuan Du
Juan Du
ZLZimo Li
Zimo Li
SCShujun Chen
Shujun Chen
XZXia Zheng
Xia Zheng
YZYu Zhang
Yu Zhang
XHXiang Hu
Xiang Hu
Endometriosis (EMs) is a chronic neuroinflammatory disorder prevalent in women of reproductive age characterized by heterogeneous clinical manifestations, while conventional Western therapies are limited by obvious adverse reactions and unsatisfactory long-term efficacy. In traditional Chinese medicine (TCM), endometriosis is categorized as "abdominal mass” and "dysmenorrhea”, and qi stagnation and blood stasis is recognized as the core pathogenic basis. TCM exerts therapeutic effects on endometriosis mainly by suppressing NF-κB-mediated inflammatory cascades, modulating immune homeostasis, balancing sex hormone secretion and abnormal angiogenesis. Clinically, herbal compound prescriptions, acupuncture and combined TCM interventions can alleviate pelvic pain, shrink ectopic lesions and cut postoperative recurrence risks. Nevertheless, the clinical application of TCM is hindered by non-unified syndrome differentiation criteria and insufficient high-level mechanistic verification. This review concludes that TCM serves as a valuable adjunctive regimen for endometriosis management; however, standardized multi-omics mechanistic exploration, large-sample randomized controlled trials and integrated Chinese-Western therapeutic protocol optimization are urgently required to facilitate the standardized formulation and international recognition of TCM for endometriosis treatment.